RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Germany’s Merck signed a non-binding MOU with China’s GenScript to form a collaboration that will offer plasmid and viral vector manufacturing, an important part of cell and gene therapy products. Merck claims to be one of only a few manufacturers with an industrialized process to make viral vectors. Merck will provide GenScript with comprehensive products, training and consulting services covering process design, facility concept design and quality management set-up from lab development to large-scale GMP manufacturing.
Source: China Biotoday
